ArticleFrontiers in microbiology2026
Impact of sequential pediatric pneumococcal conjugate vaccination (PCV10/PCV13/PCV10) on serotype distribution and antimicrobial resistance in invasive and non-invasive
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Serbia, mandatory PCV immunization was introduced in 2018, following a sequential PCV10/PCV13/PCV10 schedule. This study aimed to assess changes in pneumococcal serotype distribution, vaccine serotype coverage, antimicrobial resistance (AMR), and clonal dissemination of pediatric invasive and non-invasive isolates before and after PCV introduction. Methods: A total of 626 clinical pneumococcal isolates from children were analyzed, including 251 invasive (IPD) and 375 non-invasive (NIPD) isolates. Serotyping was performed using PCR and Quellung reactions, antimicrobial susceptibility testing followed EUCAST guidelines, and invasive isolates were further characterized by multilocus sequence typing (MLST). Serotype invasiveness ratios were evaluated in pre- (2010-2017) and post-PCV (2018-2024) periods. Results: Following PCV implementation, serotype coverage declined across all vaccines, most markedly for PCV10 (IPD: 67.7-35.6%; NIPD: 62.3-17.4%), with secondary reductions in PCV13, PCV15, and PCV20 coverage largely driven by the loss of PCV10 serotypes. The proportion of non-PCV20 serotypes rose from 7.2 to 22.9% in IPD and from 12.3 to 41.6% in NIPD, with NVTs being significantly more frequent in NIPD post-PCV period. Antimicrobial non-susceptibility decreased after PCV introduction, including significant reductions in penicillin and macrolide resistance in both IPD and NIPD isolates. Resistance levels remained higher among non-invasive isolates compared with invasive isolates. Multidrug resistance declined from 39.8 to 25.4% in IPD and from 61.0 to 29.5% in NIPD. MLST analysis showed broad clonal diversity, with ST473 and ST8144 predominating pre-PCV and ST1377 and ST320 post-PCV, together with the emergence of non-vaccine lineages and serotype switch in ST320 from 19F to 19A. Conclusion: Mandatory PCV immunization in Serbia has led to substantial shifts in pneumococcal serotype distribution, resembling patterns observed in countries relying predominantly on PCV10. Also, a reduction in antimicrobial resistance and an increase in genetic diversity were observed, highlighting ongoing serotype replacement and the need for continued integrated surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.